Chapter 1
Basic Principles

§1.01 Patents in Context
   [A] Introduction
   [B] Patents as Strategic Business Assets
   [C] Patents and Global Trade
   [D] Patents and the Public Interest
   [E] Patents as a Form of Intellectual Property (IP) Protection
       [2] IP Rights as an Incentive Mechanism
       [3] IP Rights as an Exception to Competition by Imitation

§1.02 The Right to Exclude Conveyed by a Patent
   [A] Negative, Not Positive, Right
   [B] Blocking Patents

§1.03 Policy Justifications for Patent Protection
   [A] Natural Rights
   [B] Reward for Services Rendered
   [C] Monopoly Profits Incentive
   [D] Exchange for Secrets

§1.04 Economics of the Patent System
§1.05 The Term of a Patent

[A] Length of Term

[B] Patent Term Adjustment

§1.06 Sources of U.S. Patent Law

[A] The Constitution

[B] Federal Statutes and Regulations

[C] Case Law

§1.07 Government Entities in the Patent System

[A] The U.S. Patent and Trademark Office

[B] U.S. Federal Courts

[1] U.S. District Courts

[i] Eastern District of Virginia


[3] U.S. Supreme Court

[C] U.S. International Trade Commission

Chapter 2
Patent Claims

§2.01 Introduction


[B] The Paramount Role of Patent Claims
§2.02 Components of Patent Claims

[A] Preamble

[1] Introduction

[2] Preamble Language as Claim Limiting

[B] Transition

[1] “Comprising”


[4] Other Transition Terminology

[C] Body

§2.03 Dependent Patent Claims


[B] Claim Differentiation Principle

[C] Multiple Dependent Claims

§2.04 Definiteness Requirement


[B] Perspective for Determining Claim Definiteness
§2.05 Specialized Claiming Formats

[A] Means-Plus-Function Claims

[1] Functional Claiming Generally


[B] Product-By-Process Claims

[C] Jepson Claims

[D] Markush Claims

[E] Beauregard Claims

Chapter 3

Patent-Eligible Subject Matter

§3.01 Introduction


[B] The Statutory Categories within §101

[C] Drafting Claims within the Statutory Categories

§3.02 Processes within §101

[A] Definition of a Process
[B] Process versus Product

[C] Computer-Implemented Processes

[D] Business Methods

[1] Overview


[i] *In re Bilski* (Fed. Cir. 2008) (*en banc*)


[E] Methods of Treatment

[1] Overview


[i] *Prometheus v. Mayo* (Fed. Cir. 2010)


§3.03 Machines within §101

[A] Definition of a Machine

[B] Computer-Implemented Machines

§3.04 Compositions of Matter within §101

[A] Definition of a Composition of Matter

[B] Structure versus Properties: Newly Discovered Properties of Known Compositions
Chapter 4

The Enablement Requirement

§4.01 Introduction

[A] Disclosure Requirements of Section §112, ¶1

[B] Bargain/Exchange Theory

[C] Enabling “How to Make” and “How to Use”

[D] Filing Date as Measure of Disclosure Compliance/New Matter Prohibition

[1] Incorporation by Reference

[2] Biological Deposits


§4.02 Undue Experimentation

[A] Wands Factors Framework

[B] Predictability of the Technology
[C] Scope of Enabling Disclosure Versus Scope of the Claims

[1] “Reasonable Correlation” Standard


[D] Use of Working and Prophetic Examples

§4.03 Nascent and After-Arising Technologies

Chapter 5
The Best Mode Requirement

§5.01 2011 Legislative Scale-Back of the Best Mode Requirement

§5.02 Best Mode as Enablement-Plus

§5.03 Unclear Policy Objectives

§5.04 No Best Mode Obligation in Many Foreign Countries

§5.05 Best Mode Compliance and Foreign Priority Claims

§5.06 Two-Step Analysis

[A] Step One: Subjective Inquiry

[1] Best Mode of the Inventor, not Assignee

[2] Multiple Inventors

[B] Step Two: Objective Inquiry

[1] Integrating Enablement with Best Mode

[2] Proprietary Materials

[3] Production Details and Routine Details


§5.07 Scope of the Best Mode Disclosure versus Scope of the Claims

Chapter 6

The Written Description of the Invention Requirement

§6.01 The Varied Meanings of “Written Description”

§6.02 Priority Policing Mechanism

§6.03 Policy Rationale

§6.04 “Inventor in Possession” Test


[B] Ambiguity in the Possession Test

§6.05 Written Description Versus Enablement

§6.06 Traditional “Time Gap” Situations Invoking Written Description Scrutiny

§6.07 Federal Circuit’s Expansion of the Written Description Requirement

[A] Regents of Univ. of Cal. v. Eli Lilly and Co.

[B] Enzo Biochem., Inc. v. Gen-Probe, Inc.

[C] Univ. of Rochester v. G.D. Searle & Co.


[E] Ariad Pharms., Inc. v. Eli Lilly and Co. (en banc)

§6.08 Conclusion
Chapter 7

Novelty, No Loss of Right, and Priority [Pre-America Invents Act of 2011]

Chapter Explanatory Note

§7.01 Statutory Basis: 35 U.S.C. §102

[A] Burden of Proof on USPTO

[B] Claim Interpretation in USPTO

[C] Prior Art As Defined by §102

[D] Lack of Novelty Versus Loss of Right


[F] Geographic Limitations in §102

[G] Temporal Limitations in §102

§7.02 Anticipation

[A] Definition

[B] Strict Identity Rule


[2] “Arranged As In the Claim”

[3] Exceptions to the Four Corners Rule

[4] No Analogous Art Requirement for Anticipation

[C] Species/Genus Relationships

[D] Question of Fact

§7.03 Inherent Anticipation

§7.04 Enablement Standard for Anticipatory Prior Art

[A] General Principle
Exception for Prior Art Compounds Lacking a Utility

§7.05 Anticipation under §102(a)

[A] Filing Date as *Prima Facie* Invention Date

[1] References Having Effective Date Less Than One Year Before Applicant’s Filing Date

[2] Antedating a Putative §102(a) Reference by Establishing Earlier Invention Date

[a] Generally

[b] Relying on Inventive Activity Outside the U.S. under 35 U.S.C. §104

[c] Disclaiming Affidavits

[B] “Known or Used by Others” under §102(a)

[C] “Patented” under §102(a)

[D] “Printed Publication” under §102(a)

[E] Strategies for Overcoming a §102(a) Anticipation Rejection

§7.06 Loss of Right/Statutory Bars under §102(b)

[A] Introduction

[1] Filing Date

[2] “Critical Date”

[B] Grace Period

[C] Policies Underlying the Statutory Bars

[D] “Patented” under §102(b)

[1] Conceptually Same as “Patented” Under §102(a)
“Printed Publication” under §102(b)

Public Accessibility

The Thesis Cases

Confidentiality Norms

Scientific or Technical Presentations

Internet Postings

“Public Use” Bar of §102(b)

Foundation: Egbert v. Lippmann (1881)

Public Use by Third Parties

Non-Public “Public Use”

“On Sale” Bar of §102(b)

Introduction

Policy Considerations


Post-Pfaff Decisions Interpreting “Commercial Offer”

Post-Pfaff Decisions Interpreting “Ready for Patenting”

Experimental Use Negation of the Statutory Bars

Meaning of “Negation”

Foundation: City of Elizabeth v. Nicholson Pavement (1878)

Experimental Use Factors

Must Experimental Use End with Actual Reduction to Practice?

Positioning Experimental Use within the Pfaff Framework
[I] Cannot Antedate a §102(b) Reference

[J] Cannot Rely on Paris Convention Foreign Priority Date to Remove a §102(b) Reference

§7.07 Abandonment under §102(c)

§7.08 Foreign Patenting Bar of §102(d)

[A] Policy Basis Underlying §102(d) Bar

[B] Two Prongs of §102(d)

[C] Meaning of “Patented” in §102(d)

§7.09 Description in Another's Earlier-Filed Patent Application under 35 U.S.C. §102(e)

[A] Foundation: Milburn v. Davis-Bournonville (1926)

[B] Reference Patent or Application Describes But Does Not Claim Same Invention

[C] Ameliorating the “Secret Prior Art” Problem of §102(e)

[1] Issued U.S. Patent As §102(e) Prior Art Issued U.S. Patent as §102(e) Prior Art

[2] Published U.S. Patent Application as §102(e) Prior Art

[3] Published PCT Application as §102(e) Prior Art

[D] Effective Date of §102(e) Prior Art

[1] Earliest U.S. Filing Date

[2] Reference’s Foreign Priority Date Is Not Applicable (Hilmer Rule)

[E] Provisional §102(e) Rejections

[F] Strategies for Overcoming a §102(e) Rejection
§7.10 Originality Requirement and Derivation under §102(f)

[A] Originality

[B] Derivation

[C] Qualifying as an Inventor

[D] Correcting Inventorship

§7.11 Prior Invention under §102(g)

[A] Introduction

[B] The First-to-Invent Priority Rule

[1] Statement of the Priority Rule

[2] Reduction to Practice

[a] Actual Reduction to Practice

[b] Constructive Reduction to Practice


[4] Conception

[5] Diligence

[C] Interference Proceedings under §102(g)(1)

[1] Burdens of Proof

[2] Conducted under §135(a)

[3] Time Bar Under §135(b)

[4] Reliance on Foreign Inventive Activity under §104


[D] Anticipation under §102(g)(2)

[1] Introduction
[2] Prior “Making” by Another

[3] “In this Country” Requirement


Chapter 7A

Novelty and Priority [Post-America Invents Act of 2011]

Chapter Explanatory Note


§7A.02 Sense of Congress and Legislative History for Post-AIA 35 U.S.C. §102

§7A.03 Prior Art under Post-AIA 35 U.S.C. §102(a)

[A] Introduction

[B] What Section 3 of the AIA Retained

[C] What Section 3 of the AIA Changed


[1] Invention “Patented, Described in a Printed Publication, or in Public Use, [or] On Sale” Before Effective Filing Date

[2] Invention “Otherwise Available to the Public” Before Effective Filing Date

[3] Does the AIA Permit Secret Prior Art?

§7A.04 Novelty-Preserving Exceptions under Post-AIA 35 U.S.C. §102(b)

[A] Introduction


Presumptively Novelty-Destroying Events

[1] “(A)-Type” Exceptions

[2] “(B)-Type” Exceptions


Presumptively Novelty-Destroying Events

[1] “(A)-Type” Exceptions

[2] “(B)-Type” Exceptions

§7A.05 Effective Date for AIA §3 “First Inventor to File” Amendments

§7A.06 Common Ownership under Joint Research Agreements

Chapter 8

Inventorship

§8.01 Originality Requirement

§8.02 The Process of Inventing


[1] Conception

[2] Reduction to Practice

[a] Actual Reduction to Practice

[b] Constructive Reduction to Practice

[B] The Reality
§8.03 Joint Inventors

[A] Statutory Basis

[B] Who Qualifies as a Joint Inventor?

[1] Conception as the Touchstone

[2] Quality of the Contribution

[C] Burden of Proof and Standard of Review

[D] Decisions Denying Joint Inventorship

[E] Decisions Finding Joint Inventorship

[F] The Impact of Inventorship on Ownership

§8.04 Correction of Inventorship

[A] Correction of Inventorship in Pending Patent Applications

[B] Correction of Inventorship in Issued Patents

§8.05 Derivation

[A] Derivation Defined

[B] Derivation in Patent Litigation

[C] Derivation-Related Proceedings in the USPTO

[1] Derivation as an Issue in Interference Proceedings


Chapter 9

The Nonobviousness Requirement

§9.01 Statutory Basis: 35 U.S.C. §103

§9.02 Historical Background
Hotchkiss v. Greenwood and the Elusive Requirement for “Invention”

The Hotchkiss “Ordinary Mechanic”

Replacing “Invention” with Nonobviousness

   [a] Enactment of Section 103
   [b] “Shall Not Be Negatived”
   [c] The “Person Having Ordinary Skill In The Art” (PHOSITA)
   [d] “Would Have Been” Obvious

   [a] Constitutionality of Section 103
   [b] Analytical Framework for Nonobviousness Determinations: Overview

§9.03 Graham Factor (1): Level of Ordinary Skill in the Art

§9.04 Graham Factor (2): Scope and Content of the Prior Art

[A] Terminology


[C] Section 102/Section 103 Overlap
   [1] In re Bass (C.C.P.A. 1973)
   [2] Section 103(c) Exclusion of Commonly-Owned Subject Matter
   [3] Section 103(c) Exclusion of Joint Research Work
   [4] Use of Temporarily Secret Prior Art to Establish Obviousness

[D] Analogous Art
§9.05  *Graham* Factor (3): Differences between Claimed Invention and Prior Art

§9.06  *Graham* Factor (4): Secondary Considerations

[A] Evidentiary Weight

[B] Commercial Success

[1] Nexus Requirement

[C] Long Felt But Unsolved Needs

[D] Failure of Others

[E] “Etc.”

[1] Copying

[2] Licensing

§9.07  Combining Prior Art Disclosures

[A] Teaching, Suggestion, or Motivation (TSM) to Combine

[B] Reasonable Expectation of Success

[C] “Obvious to Try” (pre-*KSR* Meaning)

[D] Unexpected Results

[E] Teaching Away


[A] Expanding the Reasons for Combining Prior Art Disclosures

[B] Common Sense

[C] Requirement for Explicit Analysis

[D] Redefining “Obvious to Try”
[E] Predictability

[F] Representative Federal Circuit Applications of KSR
   [1] Mechanical Inventions
   [3] Pharmaceutical and Biotechnology Inventions

§9.09 The Prima Facie Case of Obviousness

§9.10 Federal Circuit’s Standards of Review for §103 Determinations
   [A] USPTO
      [1] Factual Findings
   [B] Federal District Court
      [1] Factual Findings by Court

§9.11 Biotechnological Processes: Section 103(b)

Chapter 10

The Utility Requirement

§10.01 Statutory Basis: 35 U.S.C. §101

§10.02 Practical/Real-World Utility

§10.03 Historical Development
   [A] Justice Story’s Standard

§10.04 Federal Circuit Examples
[A] Chemical Compounds
[B] Methods of Treating Disease
[C] Genetic Inventions

§10.05 USPTO Examination Guidelines on Utility

§10.06 Inoperability

[A] Examples of Inoperable Inventions
[B] Inoperable Species within a Genus

§10.07 Immoral or Deceptive Inventions

§10.08 Utility Versus How-to-Use Requirement of §112, ¶1

Chapter 11
Patent Prosecution Procedures in the USPTO

§11.01 Introduction

§11.02 Filing the Patent Application

[A] Non-Provisional/Regular Application
[B] Provisional Application

§11.03 Examination by the USPTO

[A] Overview
[B] Search of Prior Art
[C] First Office Action
[D] Applicant’s Response
[E] Second or Final Office Action
[F] Requests for Continued Examination
[G] Continuing Applications

§11.04 Patent Issuance

§11.05 Patent Term Adjustment

§11.06 Publication of Pending Nonprovisional Applications

§11.07 Continuing Application Practice

[A] Introduction

[B] Three Types of Continuing Applications

[C] Filing Requirements

[D] Effective Filing Date of Claims in Continuing Applications

[E] Patent Term of Continuing Applications

[F] Divisional Applications

[1] Restriction Requirements

[2] Consonance Requirement

§11.08 Claiming Foreign Priority

[A] Treaty Basis and Statutory Implementation

[B] “Shall Have the Same Effect”

[C] “Same Invention”

[D] Formal Requirements

[E] First-Filed Foreign Applications

§11.09 Appeals to the USPTO Board of Patent Appeals and Interferences

§11.10 Civil Actions for a Patent

§11.11 Sample Office Action and Applicant’s Response

§11.12 Sample Patent and its Components
Chapter 12

Double Patenting

§12.01 Introduction

§12.02 Two Types of Double Patenting

[A] Same Invention-Type

[B] Obviousness-Type

§12.03 Policy Bases

[A] Prevent Improper Extension of Patentee’s Right to Exclude Others

[B] Prevent Potential Harassment by Multiple Assignees

§12.04 Foundational Case Study

§12.05 Twenty-Year Patent Term Did Not Eliminate Double Patenting Concerns

§12.06 How Double Patenting Differs from Anticipation and Obviousness

[A] Claim-to-Claim Comparison

[B] Prior Art is Not Involved

[C] Similarities

§12.07 Proper Use of the Disclosure to Interpret the Claims

§12.08 Improper Use of the Disclosure as Prior Art

§12.09 Use of Terminal Disclaimer to Overcome Obviousness-Type Double Patenting

[A] Terminal Disclaimers in the USPTO

[B] Terminal Disclaimers in Litigation

§12.10 One-Way versus Two-Way Test for Obviousness-Type Double Patenting